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Abstract- Lithium is a drug used for the treatment of bipolar disorder. It has several mechanisms of action, 
and recently it is shown that lithium can antagonize the 5-HT1B/1D serotonin receptors. Sumatriptan is a 5-
HT1B/1D receptor agonist used for the treatment of cluster headaches and migraine which might cause 
memory impairment as a potential side effect. In this study, effects of lithium on sumatriptan-induced 
memory impairment have been determined in a two-trial recognition Y-maze and passive avoidance tests. 
Male mice weighing 25-30 g were divided into several groups randomly. In Y-maze test, effects of lithium 
(1,5,10,20,40,80 mg/kg) and sumatriptan (1,5,10 mg/kg) were assessed on memory acquisition, then lithium 
(0.1,1,10 mg/kg) and sumatriptan (1,10 mg/kg) were studied in passive avoidance test. Effects of lithium 
(1mg/kg) on sumatriptan (10 mg/kg)-induced memory impairment were studied in both of tests. The present 
study demonstrated that sumatriptan impaired memory in Y-maze and passive avoidance tests (P<0.05, 
P<0.01, respectively). Lithium did not show any significant effect on memory function compared to saline-
treated control group in both tests (P>0.05), but significantly reversed sumatriptan-induced memory 
impairment in Y-maze and passive avoidance tests (P<0.001, P<0.05, respectively). It is concluded that 
lithium reverses the sumatriptan-induced memory impairment probably through 5-HT1B/1D receptors 
antagonism. 
© 2016 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran, 2016;54(4):226-232. 
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Introduction 
 
Sumatriptan is a 5-HT1B/1D receptor agonist (1). 
Since this receptor is coupled to Gi (2,3), studies have 
shown that stimulation of these receptors reduces the 
release of neurotransmitter (4-6). This drug with the 
same mechanism reduces the release of calcitonin gene-
related peptide (CGRP) (7). 
Considering the fact that sumatriptan decreases the 
release of various neurotransmitters, it is likely to cause 
memory impairment. Several studies have shown that 
part of the therapeutic effects of lithium may be due to 
inhibitory receptors 5-HT1B/1D (8-10). Perhaps part of 
the effects of lithium on memory is due to 5-HT1B/1D 
receptor antagonism (11), so the aim of the present study 
was to evaluate the effects of lithium on sumatriptan-
induced memory impairment in a two trial recognition 
Y-maze test and passive avoidance in mice. 
 
Materials and Methods 
 
Housing and handling of the animals 
The animals were handled in accordance with the 
criteria outlined in the Guide for the Care and Use of 
Laboratory Animals (NIH US publication 86–23 revised 
1985). NMRI mice (Pasteur institute Tehran, Iran), 6-8 
weeks of age, were kept in a controlled environment 
(23±2 °C, 50±5% humidity) under a 12-h light/dark 
cycle (light on 08:00-20:00) and had free access to a 
standard pellet chow and tap water throughout the study. 
Each mouse was used only once, and each mouse was 
used once and each treatment group comprised of 8-12 
animals. Animals were excluded if they remained 
immobile during the test, or they resisted swallowing the 
drug and threw it out. 
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Chemicals and drugs 
Sumatriptan used in this study were purchased from 
Sigma-Aldrich (St. Louis, MO, USA), and lithium was 
purchased from Merck (Darmstadt, Germany). All drugs 
were freshly diluted in physiological saline. Lithium and 
sumatriptan were administrated intraperitoneally and 
subcutaneous, respectively 
 
Y-maze task 
The Y-maze is a simple two-trial recognition test for 
evaluating spatial recognition memory. It is based on the 
innate tendency of rodents to explore novel 
environments (12). It consists of three horizontal arms 
(40 cm long, 3 cm wide walls and 12 cm high) 
symmetrically disposed at 120° to each other. Each arm 
had different clues for distinction from each other. The 
Y-maze test comprised two trials separated by a 1 h 
inter-trial interval. In the first trial (training), which 
lasted 10 min, each mouse was placed at the end of the 
start arm and was allowed to explore only two arms 
(including the start arm), with the third arm (novel arm) 
being blocked. After 1 h, in the second trial (retention), 
the mouse was placed back in the maze, at the same start 
arm with free access to all three arms, being allowed to 
move freely during an 8 min period. The number of arm 
entries and exploration time in each arm were recorded 
using a video tracking software (EthoVision, Noldus, 
The Netherlands) for each mouse over an 8 min period. 
The total number of arm entries and distance moved 
were measured as indexes of locomotors activity to rule 
out the interference of changes in motility with the 
parameters of learning and memory. To avoid the 
presence of olfactory trials, maze arms were thoroughly 
cleaned between tests. 
Recognition of the novel arm from the other two 
familiar arms is considered as a memory improvement 
effect. Mice which distinguish the unfamiliar arm show 
exploratory behavior, so they spend more time and enter 
more frequently to the novel arm in comparison with the 
other familiar ones. 
 
Passive avoidance task 
Passive avoidance apparatus was consisted of a two 
identical compartments (20×20×20 cm), illuminated and 
non-illuminated boxes (Borj Sanat Company, Tehran, 
Iran), separated by a guillotine door. The illuminated 
compartment contained a 40W bulb, and the floor of the 
non-illuminated compartment was composed of 2 mm 
stainless steel rods spaced 1 cm apart. During the 
training trial, each mouse was placed in the lighted 
compartment, and when the mouse entered the dark 
compartment the door closed, and the mouse received an 
inescapable electric shock (0.5 mA, 1 s). The test trial 
was done 24 h after the training trial; in this step, the 
mouse was again placed in the lighted compartment and 
the latency time to enter the dark compartment was 
measured. If the mouse did not enter the dark chamber 
within the cut-off time (300 s), it was assigned a latency 
value of 300 sec (13). 
 
Experimental design 
Y-maze  
Mice were administered different doses of lithium 
(1,5,10,20,40,80 mg/kg) intraperitoneally 60 min before 
the training trial. In another group, sumatriptan (1,5, and 
10 mg/kg) 30 min the training trial was administrated 
subcutaneously, and the third group was co-
administrated lithium (1 mg/kg) and sumatriptan (10 
mg/kg) 60 min and 30 min before training trial, 
respectively.  
 
Passive avoidance 
In the first group, different doses of lithium (0.1,1, and 
10 mg/kg) were injected intraperitoneally 60 min before 
the training trial. In the second group, sumatriptan (10 
mg/kg) 30 min before the training trial was administrated 
subcutaneously, and the third group was co-administrated 
lithium (1 mg/kg) and sumatriptan (10 mg/kg) 60 min and 
30 min before training trial, respectively.  
 
Statistical analysis 
Statistical analyses were carried out using GraphPad 
Prism 5 software (San Diego, CA, USA). The results are 
presented as mean ± S.E.M. Differences among 
treatment groups were considered as between-group 
factor, whereas differences in arm entries and 
exploration time for each special treatment were 
considered as a within-group factor. Each of between-
group differences in the determination of exploration 
time and number of arm entries in Y-maze was assessed 
with multivariate analysis of variance (ANOVA) and 
Tukey’s post-hoc test. The non-parametric ANOVA 
using a medians test was applied to analyze the result of 
passive avoidance data. Moreover, one-way ANOVA 
was used to determine the within-group differences in 
locomotor activities, and P values less than 0.05 were 
considered statistically significant. 
 
Results 
 
Y-maze test 
Injection of different doses of lithium could not alter 
Lithium and sumatriptan-induced memory impairment  
228    Acta Medica Iranica, Vol. 54, No. 4 (2016)  
the time spent in the novel arm, significantly (P>0.05, 
Figure 1). 
 
 
 
Figure 1. Time spent in the various arms of the groups receiving lithium 
 
 
Sumatriptan at a dose of 10 mg/kg could reduce the 
time spent in the novel arm, compared to saline group 
(P<0.05, Figure 2). 
 
 
Figure 2. Time spent in the various arms of the groups receiving sumatriptan 
 The significant difference with the corresponding arm of the saline group, *:P<0.05. 
 
 
As Figure 3 shows, the time spent in the novel arm 
of the group receiving coadministration of lithium and 
sumatriptan at doses of 1 mg/kg and 10 mg/kg 
respectively was significantly greater than the group 
receiving a dose of 10 mg/kg of sumatriptan alone 
(P<0.001). In this regard, the time spent in the start arm 
of the group injected with combination of lithium and 
sumatriptan at mentioned doses was significantly lesser 
than the group treated with a dose of sumatriptan (10 
mg/kg) alone (P<0.01, Figure 3). 
 
 
Figure 3. Time spent in the various arms of the lithium and sumatriptan co-administration group 
The significant difference with the corresponding arm of the saline group, *: P<0.05. The significant difference with the corresponding arm of 
sumatriptan 10 group, #: P<0.001, +: P<0.01. 
 
 
In the case of entry into each arm, all groups showed 
a significant difference in the percentage of novel arm 
entries compared with saline group (P<0.05, Figure 4). 
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Figure 4. Percent of arm visits in different groups. The significant difference with the new arm of the saline group, *: P<0.05. 
 
However, no significant differences were observed 
between groups in locomotor activity parameters 
including the total number of arm entries, and total 
distance moved in arms (P>0.05, Figure 5). 
 
 
Figure 5. Locomotor activity in different groups 
 
 
Passive avoidance test 
Figure 6 demonstrates the effect of lithium on 
memory in step-through latency (STL). Different doses 
of lithium (0.1 mg/kg, 1 mg/kg, and 10 mg/kg) 
administered 60 min before training test did not show 
any significant difference in latency time in comparison 
with saline group (P>0.05, Figure 6). 
 
 
Figure 6. Step-through latency time in the acquisition of memory in the groups receiving lithium 
 
 
In STL using the passive avoidance paradigm, 
sumatriptan (10 mg/kg) administered 30 min prior to a 
training session, significantly decreased the latency time 
compared with saline group (P<0.01, Figure 7). 
 
 
Figure 7. Step-through latency time in the acquisition of memory in the groups receiving sumatriptan 
The significant difference with the latency of retention trial of the saline group, *: P<0.01 
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Demonstrating in Figure 8, lithium (1 mg/kg) 
administered 60 min before the training session, could 
reverse the sumatriptan-induced memory impairment in 
passive avoidance test (P<0.05), while it had no effect 
on latency time by itself (P>0.05, Figure 6). 
 
 
Figure 8. Step-through latency time in the acquisition of memory in lithium and sumatriptan co-administration group 
The significant difference with the latency of retention trial of the saline group, *: P<0.01. The significant difference with the latency of retention 
trial of sumatriptan 10 group, #: P<0.05 
 
 
Discussion 
 
Alzheimer’s disease is the most common cause of 
progressive intellectual failure in aged humans. 
Advancing age increases the risk of acquiring 
Alzheimer’s disease. In the present study, we showed 
for the first time that administration of lithium (1 mg/kg) 
could reverse memory impairment induced by 
sumatriptan (10 mg/kg). To investigate the effect of 
drugs on memory acquisition, we used Y-maze task as a 
specific test of short-term spatial recognition memory 
and the passive avoidance task for the long-term 
memory status. Our findings showed that lithium could 
opposite the sumatriptan-induced memory impairment in 
both tests, whereas it was unable to exert any significant 
effect on memory by itself (Figures 1, 6). 
Lithium is a drug commonly used for maintenance 
treatment of manic and unipolar and bipolar depression. 
Many studies have pointed out the dual effects of 
lithium on memory consolidation and destruction. 
Creson et al., in 2003 in a trial to assess short-term 
memory in dose-response fish studies, using different 
doses of lithium concluded that in all of these groups, 
varying degrees of memory impairment, but 
independently of the dose can be observed (14). Some 
other studies have also shown that lithium can cause 
memory impairment (15,16). A recent study by 
Honarmand et al., in 2014 reported that among different 
doses of lithium (5,10,20, and 40 mg/kg), the dose of 40 
mg/kg of lithium could significantly impair the 
acquisition of spatial recognition memory in mice. 
Anyway, we did not show any significant effect of 
lithium on short-term and long-term memory in a wide 
range of lithium in both tests, which might attribute to 
ambiguous effects of lithium on memory. 
Many experimental studies in animals, however, are 
contrary to the above mentioned. Tsaltas et al., in 2007 
reported that lithium may increase spatial memory in 
rats (8). Inhibition of glycogen synthase kinase-3 (GSK-
3) by lithium causes the accumulation of beta-catenin in 
the brain, which plays a role in memory consolidation 
(9,10). 
Physiological, pathophysiological, and therapeutic 
roles of 5-HT systems in learning and memory are 
described frequently (17). Among 5-HT receptors, 5-
HT1B/1D and 5-HT1A receptors are more related to 
memory (18,19). For instance, Malleret et al. reported 
that 5-HT1B receptor knock-out mice exhibit increased 
exploratory activity and enhanced spatial memory 
performance in the Morris water maze (20). Similarly, 
Meneses et al. showed that stimulation of presynaptic 5-
HT1B/1D receptors impairs the consolidation of 
learning in male rats (19). In the present study, we 
showed memory impairment by a 5-HT1B/1D agonist, 
sumatriptan, which corroborates with previous 
experiments. 
Schechter et al., have shown that 5-HT1B/1D 
receptor antagonists increase the performance and the 
signaling between neurons involved in the process of 
cognition and memory (21). Harder et al. also reported 
that the 5-HT1A receptor antagonists to prevent the 
process of memory loss in Alzheimer’s disease (22). The 
results of these studies are in agreement with findings of 
the present study based on a memory corruption by 
sumatriptan, as well as the abolishment of this event by 
lithium. 
Results of the present study implicate the regulatory 
effects of 5-HT1B/1D receptors in memory 
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performance, reflecting in impairment of memory by 5-
HT1B/1D receptor agonist, sumatriptan. Based on this 
event, lithium as a 5-HT1B/1D receptor antagonist was 
anticipated to might potentiate memory performance, 
which was reported in aforementioned experiments 
(8,9). Anyway, though lithium could not show memory 
enhancement significantly, but obviously reversed 
sumatriptan-induced memory impairment in both tests. 
According to the findings of the present study, 
inhibition of 5-HT1B/1D receptors by lithium might 
reverse memory deficits induced by 5-HT1B/1D 
receptor agonists such as sumatriptan. In other words, a 
part of the effects of lithium on memory is due to 
5HT1B/1D receptor antagonism. However, to clarify 
this issue, further studies on the interactions of lithium 
with other 5HT1B/1D receptor agonists in animal 
models of memory seems necessary. 
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